Bempedoic Acid

證據等級: L5

預測適應症: 10 個

Bempedoic Acid: From Hypercholesterolemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Bempedoic acid is an ATP-citrate lyase (ACL) inhibitor used to lower LDL-cholesterol in patients with hypercholesterolemia/atherosclerotic cardiovascular disease who need additional LDL-C reduction beyond statins. Among the TxGNN-predicted indications, the top-ranked candidate (hyperthyroidism, score 99.61%) was reviewed and found to have no credible mechanistic or literature support — it is flagged as likely model noise. The strongest evidence-backed candidate is Homozygous Familial Hypercholesterolemia (HoFH), supported by 1 real-world cohort study and 17 supporting publications, reaching Evidence Level L3.

Quick Overview

Item	Content
Original Indication	Not on file in the regulatory dataset (drug not marketed locally); literature confirms established use as an LDL-C–lowering agent for hypercholesterolemia / ASCVD risk reduction, used alongside statins, ezetimibe, and PCSK9 inhibitors
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.48% (rank #6 among predictions; rank #1 "hyperthyroidism" excluded — see note below)
Evidence Level	L3
Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Note on TxGNN ranking: The single highest TxGNN score (hyperthyroidism, 99.61%) was cross-checked against its supporting literature and found to reference an unrelated drug (tiratricol) with no mechanistic connection to bempedoic acid. Ranks #2–5, #7–10 (thyroid hormone resistance, malignant catarrh, bovine rhinotracheitis, CMV infection, hyperthyroxinemia, drug-induced osteoporosis, MEN, pregnancy-associated osteoporosis) similarly have zero supporting evidence and no plausible mechanism. This report therefore focuses on the one candidate with real evidentiary support: HoFH.

Why is This Prediction Reasonable?

Bempedoic acid inhibits ATP-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the hepatic cholesterol biosynthesis pathway. It is a prodrug activated by ACSVL1, an enzyme expressed almost exclusively in the liver and absent in skeletal muscle — this liver-restricted activation is why bempedoic acid does not carry the same myopathy risk as statins. ACL inhibition upregulates hepatic LDL receptor (LDLR) expression and lowers LDL-C independently of, and additively to, statin therapy.

HoFH is a rare genetic disorder in which LDLR function is severely or completely deficient, producing extremely elevated LDL-C and early-onset atherosclerotic cardiovascular disease. Because LDLR function is so impaired, HoFH management typically requires combination therapy (statins, ezetimibe, PCSK9 inhibitors, evinacumab, lomitapide) to achieve any meaningful LDL-C reduction. Bempedoic acid's LDLR-upregulating, largely LDLR-independent mechanism makes it mechanistically plausible as an add-on agent in this population, and a 2026 real-world cohort study (PMID 41274797) already reports its use specifically in HoFH patients.

This is best understood not as a novel disease-area repurposing, but as an indication extension within the same lipid-disorder therapeutic space the drug already occupies — which is a much lower-risk, higher-plausibility form of repurposing than the noise-driven candidates elsewhere in the TxGNN output.

Clinical Trial Evidence

Currently no related clinical trials registered specifically for HoFH.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
41274797	2026	Cohort (real-world)	J Clin Lipidol	Direct real-world evaluation of bempedoic acid efficacy/tolerability specifically in HoFH patients
41741298	2026	Expert consensus	J Clin Lipidol	National Lipid Association update on FH management, incorporating current LDL-C-lowering options
41694628	2026	Case report + review	Clin Case Rep	Illustrates consequences of interrupted HoFH follow-up; reviews aggressive LDL-C-lowering strategies
41106315	2025	Review	Exp Mol Pathol	Reviews innovative HoFH therapies including non-statin LDL-C-lowering agents
35466160	2022	Review	J Atheroscler Thromb	Reviews advancements in HoFH treatment, positioning bempedoic acid among newer options
37071085	2024	Review	Cardiol Rev	Discusses evinacumab and other add-on therapies (incl. bempedoic acid) for HoFH
29449335	2018	Preclinical (animal model)	Arterioscler Thromb Vasc Biol	Bempedoic acid lowers LDL-C and attenuates atherosclerosis in LDLR-deficient miniature pigs — direct mechanistic support for LDLR-independent benefit
33766264	2021	Review	J Am Coll Cardiol	Reviews emerging LDL-C/ApoB-lowering therapies including bempedoic acid alongside PCSK9i and inclisiran
38576462	2024	Review	Am J Prev Cardiol	Emphasizes cumulative LDL-C exposure as ASCVD driver, supporting rationale for maximal LDL-C reduction in high-risk groups like HoFH
32243228	2020	Review	Postgrad Med	Reviews emerging LDL-C-lowering agents including bempedoic acid's mechanism and clinical positioning

Norway Market Information

This drug is not currently marketed in the evaluated jurisdiction (0 authorizations on file); no license records are available to summarize approved indications or dosage forms.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A mechanistically plausible, LDLR-independent LDL-C-lowering effect is supported by preclinical data in an LDLR-deficient animal model and a real-world clinical cohort specifically in HoFH patients, but no dedicated randomized controlled trial in HoFH exists yet — evidence is promising but not conclusive (L3).

To proceed, the following is needed:

Official mechanism of action (MOA) documentation from the regulatory label/DrugBank (currently flagged as Data Gap, DG002)
Local regulatory label warnings, contraindications, and DDI data (currently flagged as Blocking Data Gap, DG001) — required before any safety-based decision can be finalized
A dedicated prospective or randomized trial evaluating bempedoic acid as add-on therapy in HoFH
Local market authorization pathway assessment, since the drug is not currently marketed in this jurisdiction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.